Mesa Laboratories 2026 Q2 Earnings Net Income Drops 27.8% Despite Revenue Growth

Mesa Laboratories (MLAB) reported fiscal 2026 Q2 earnings on November 7, 2025. . However, , and management acknowledged ongoing challenges in (CG) China. Guidance highlighted sequential revenue growth in Q3 and continued CG China declines, with cost savings reinvested into long-term SDC growth.

Revenue

, driven by strong performance in and Calibration Solutions. Sterilization and Disinfection Control (SDC) faced softness, . However, , attributed to macroeconomic and regulatory headwinds, offset gains. , , fueled by Peptides instrument sales. , .

Earnings/Net Income

, . Despite the decline, , the highest in over two decades. , , .

Post-Earnings Price Action Review

Mesa Laboratories’ shares have shown mixed momentum post-earnings. , , reflecting broader market skepticism. Analysts remain cautiously optimistic, . , though long-term challenges in CG China persist.

CEO Commentary

, driven by BPD, CS, and CG (excluding China), despite SDC and CG China struggles. , , were implemented, . Strategic initiatives like and events aim to enhance customer engagement and long-term growth. Owens expressed confidence in operational resilience amid macroeconomic uncertainty.

Guidance

. . . , with strategic initiatives targeting SDC and CG (outside China) expansion.

Additional News

Analysts maintain a “buy” consensus rating for MLAB, with one “strong buy,” two “hold,” and no “sell” recommendations. The peer group average also supports a “buy” stance. . , . No major M&A activity, C-level changes, or dividend/buyback news was reported within three weeks of the earnings release.